MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Total Liabilities 2011-2026 | BMY
Annual Total Liabilities Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71.5 B | 76.2 B | 65.7 B | 65.7 B | 73.3 B | 80.6 B | 78.2 B | 20.9 B | 21.7 B | 17.4 B | 17.3 B | 18.8 B | 23.4 B | 22.3 B | 17.1 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 80.6 B | 17.1 B | 44.7 B |
Quarterly Total Liabilities Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.2 B | 75 B | 76.5 B | 77.6 B | 82.5 B | 62.2 B | 61.5 B | 62.4 B | 65.7 B | 65.5 B | - | 71.4 B | 73.3 B | 73.6 B | 73.9 B | 74.8 B | 80.6 B | 80.6 B | 80.6 B | 80.6 B | 78.2 B | 78.2 B | 78.2 B | 78.2 B | 20.9 B | 20.9 B | 20.9 B | 20.9 B | 21.7 B | 21.7 B | 21.7 B | 21.7 B | 17.4 B | 17.4 B | 17.4 B | 17.4 B | 17.3 B | 17.3 B | 17.3 B | 17.3 B | 18.8 B | 18.8 B | 18.8 B | 18.8 B | 23.4 B | 23.4 B | 23.4 B | 23.4 B | 22.3 B | 22.3 B | 22.3 B | 22.3 B | 17.1 B | 17.1 B | 17.1 B | 17.1 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82.5 B | 17.1 B | 42.6 B |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
263 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Axsome Therapeutics
AXSM
|
602 M | $ 163.89 | - | $ 8.15 B | USA |
 |
BridgeBio Pharma
BBIO
|
3.01 B | $ 64.28 | -3.31 % | $ 12.3 B | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
BioCardia
BCDA
|
4.59 M | $ 1.37 | 5.81 % | $ 29 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioLineRx Ltd.
BLRX
|
25.4 M | $ 2.82 | -0.35 % | $ 908 M |  Israel |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioMarin Pharmaceutical
BMRN
|
1.51 B | $ 59.8 | -3.13 % | $ 11.5 B | USA |
 |
Benitec Biopharma
BNTC
|
2.3 M | $ 10.93 | 0.23 % | $ 450 M | USA |
 |
BioNTech SE
BNTX
|
3.12 B | $ 109.33 | -0.82 % | $ 27.2 B | Germany |
 |
Black Diamond Therapeutics
BDTX
|
39.4 M | $ 2.38 | -3.44 % | $ 131 M | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
BioXcel Therapeutics
BTAI
|
131 M | $ 1.63 | -2.4 % | $ 4.13 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M |  Canada |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.65 | 2.49 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
BeyondSpring
BYSI
|
48.6 M | $ 1.34 | -0.87 % | $ 54 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Cabaletta Bio
CABA
|
17.5 M | $ 3.34 | 0.61 % | $ 3.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 4.88 | 2.74 % | $ 10.6 B | Israel |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
Capricor Therapeutics
CAPR
|
36.1 M | $ 27.28 | -2.32 % | $ 731 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 11.67 | -3.47 % | $ 768 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
C4 Therapeutics
CCCC
|
102 M | $ 3.06 | 13.3 % | $ 254 M | USA |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | USA |
 |
Codexis
CDXS
|
82.1 M | $ 0.99 | -2.04 % | $ 72.7 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |